Reckitt Benckiser Announces Completion of Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics, Inc.
24 Enero 2008 - 6:00AM
PR Newswire (US)
CHESTER, N.J. and SLOUGH, England, Jan. 24 /PRNewswire-FirstCall/
-- Reckitt Benckiser Group plc (RB.L) ("Reckitt Benckiser")
announced today that it has completed its previously announced cash
tender offer (the "Offer") for all outstanding shares of common
stock (the "Shares") of Adams Respiratory Therapeutics, Inc.
(NASDAQ:ARxT) ("Adams"). The Offer expired, as scheduled, at
midnight, New York City time, at the end of Wednesday, January 23,
2008. The Offer was not extended. A total of 34,623,895 Shares had
been tendered and not withdrawn prior to the expiration of the
Offer, including 2,637,863 Shares subject to guaranteed delivery
procedures. Reckitt Benckiser has accepted for payment all validly
tendered Shares through its indirect wholly owned subsidiary,
Twickenham Inc. The Shares accepted for payment represent
approximately 95.9% of the outstanding Shares of Adams. Payment for
these validly tendered Shares is expected to be made promptly. As
the final step of the acquisition process, Reckitt Benckiser
intends to consummate a merger in which remaining Adams
stockholders will receive the same US$60.00 in cash per share paid
in the Offer. Consummation of the merger is expected to occur on
January 29, 2008. Following the merger, Adams will become an
indirect wholly owned subsidiary of Reckitt Benckiser. Notes for
Editors Reckitt Benckiser is a world leader in household cleaning,
health and personal care. The Company is truly global, with over 60
operating companies and some 43 manufacturing facilities worldwide
and has sales in 180 countries. Reckitt Benckiser employs 22,000
people around the world. Amongst the Company's leading brands in
household are Lysol, the world leader in disinfecting cleaning,
Calgonit & Finish & Electrasol, the world leaders in
automatic dishwashing, Woolite, world leader in fine fabrics,
Vanish & Spray'nWash, world leaders in fabric treatment,
Airwick and Mortein, both No.2 brands in air care and pest control
respectively. In Health & Personal Care (25% of net revenues),
leading brand positions include Veet, the world number one
depilatory and Dettol the world's leading antiseptic, Nurofen, the
leading European analgesic, Strepsils, world number one in
medicated sore throat, Gaviscon the No.1 gastro intestinal remedy
in UK and Lemsip the UK no.1. in cold/flu remedies. Reckitt
Benckiser is headquartered in Slough just outside London, UK and is
listed on the London stock exchange. Reckitt Benckiser had net
revenues of pounds Sterling 4.92bn, operating profit of pounds
910m, and net income of pounds 674m in 2006. About Adams
Respiratory Therapeutics, Inc. Adams is a specialty pharmaceutical
company focused on the late-stage development, commercialization
and marketing of over-the-counter and prescription pharmaceuticals
for the treatment of respiratory disorders. DATASOURCE: Adams
Respiratory Therapeutics, Inc. CONTACT: Mark Wilson, Corporate
Controller and Acting Head of Investor Relations (investor
queries), Fiona Fong, Head of Corporate Communications (press
queries), both of Reckitt Benckiser, +44 (0) 1753 217 800; Susan
Gilchrist of Brunswick, +44 (0) 207 404 5959, or Cindy Leggett
Flynn of Brunswick New York, +1-212-333-3810; Janet M. Barth, SVP
Investor Relations & Corporate Communications, +1-908-879-2428,
or Faith Pomeroy-Ward, Sr. Manager Investor Relations &
Corporate Communications, +1-908-879-1418, both of Adams
Respiratory Therapeutics, Inc. Web site: http://www.adamsrt.com/
Copyright